Georgakis Georgios V, Younes Anas
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Expert Rev Anticancer Ther. 2006 Jan;6(1):131-40. doi: 10.1586/14737140.6.1.131.
One of the most prominent pathways explored in the area of targeted therapy is the PI3K/Akt/mTOR pathway, which plays a central role in cell survival and proliferation. Deregulation of this pathway has been implicated in the promotion of cancer cell growth and survival. Inhibition of several steps of this pathway has been shown to confer favorable antitumor activity in a variety of cancer types. This article provides a brief analysis of the PI3K/Akt/mTOR pathway, its importance in tumor pathogenesis and the current status of preclinical and clinical studies targeting signaling components of this pathway.
在靶向治疗领域探索的最突出途径之一是PI3K/Akt/mTOR途径，它在细胞存活和增殖中起核心作用。该途径的失调与癌细胞生长和存活的促进有关。已证明抑制该途径的几个步骤在多种癌症类型中具有良好的抗肿瘤活性。本文简要分析了PI3K/Akt/mTOR途径、其在肿瘤发病机制中的重要性以及针对该途径信号成分的临床前和临床研究现状。
